Please use this identifier to cite or link to this item:
|Title:||TRIPS and Parallel Imports — Impact on Drug Prices|
|Authors:||Nair, M D|
|Abstract:||<smarttagtype namespaceuri="urn:schemas-microsoft-com:office:smarttags" name="City"><smarttagtype namespaceuri="urn:schemas-microsoft-com:office:smarttags" name="country-region"><smarttagtype namespaceuri="urn:schemas-microsoft-com:office:smarttags" name="place"> In the ‘parallel imports’ products are made and marketed by the patent owner (or trademark- or copyright-owner, etc.) in one country and imported into another country without the approval of the patent owner. The legal principle here is ‘exhaustion’, the idea that once a company has sold its product, its patent is exhausted and it no longer has any rights over what happens to that product. It is a method of ensuring affordable access to essential goods. The paper discusses in detail the various provisions of TRIPS related to parallel imports and how it is being dealt with in USA, European Union, UK, Japan and Australia, and outlines the impact of parallel imports on prices. Some suggestions for enforcing ‘exhaustion regime’ in India are given. </smarttagtype></smarttagtype></smarttagtype>|
|ISSN:||0975-1076 (Online); 0971-7544 (Print)|
|Appears in Collections:||JIPR Vol.07(4) [July 2002]|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.